 Accelerate Diagnostics, Inc. NASDAQ: AXDX and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that the U.S. Food and Drug Administration FDA has issued an Emergency Use Authorization EUA for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument. 